摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine trihydrochloride

中文名称
——
中文别名
——
英文名称
(1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine trihydrochloride
英文别名
(1H-Indazol-5-yl)-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine hydrochloride;N-(1H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;hydrochloride
(1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine trihydrochloride化学式
CAS
——
化学式
C18H17N7*3ClH
mdl
——
分子量
440.763
InChiKey
SOLMMVLGPLQDMJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.38
  • 重原子数:
    26
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    94.3
  • 氢给体数:
    5
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
    申请人:Ahmed Saleh
    公开号:US20060211678A1
    公开(公告)日:2006-09-21
    Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    化合物式(I)所代表的化合物,或其立体异构体或药学上可接受的盐,是动物,包括人类体内至少两种Abl,Aurora-A,Blk,c-Raf,cSRC,Src,PRK2,FGFR3,Flt3,Lck,Mek1,PDK-1,GSK3β,EGFR,p70S6K,BMX,SGK,CaMKII,Tie-2,IGF-1R,Ron,Ret和KDR激酶的抑制剂,用于治疗和/或预防各种疾病和病症,如癌症。
  • Substituted pyrrolo[2.3-B]pyridines
    申请人:OSI Pharmaceuticals, Inc.
    公开号:US07465726B2
    公开(公告)日:2008-12-16
    Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    公式(I)所代表的化合物,或其立体异构体或药学上可接受的盐,是动物,包括人类中至少两种Abl,Aurora-A,Blk,c-Raf,cSRC,Src,PRK2,FGFR3,Flt3,Lck,Mek1,PDK-1,GSK3β,EGFR,p70S6K,BMX,SGK,CaMKII,Tie-2,IGF-1R,Ron,Ret和KDR激酶的抑制剂,用于治疗和/或预防各种疾病和病况,如癌症。
  • ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS
    申请人:OSI Pharmaceuticals, Inc.
    公开号:EP1797054A2
    公开(公告)日:2007-06-20
  • US7465726B2
    申请人:——
    公开号:US7465726B2
    公开(公告)日:2008-12-16
  • [EN] ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS<br/>[FR] COMPOSES A BASE DE PYRROLOPYRIMIDINE A SUBSTITUTION ARYLAMINE INHIBITEURS DE KINASES MULTIPLES
    申请人:OSI PHARM INC
    公开号:WO2006017443A3
    公开(公告)日:2007-01-18
查看更多